


VCTE-Prognosis Study Group


- 17,949 patients with MASLD who underwent VCTE from 16 centers (prospective at 14 centers)
- 14,845 Asian countries/regions
 - 9,556 Korea
 - 4,037 Hong Kong
 - 474 Japan
 - 366 China
 - 211 Singapore
 - 201 Malaysia
- 3,104 Western countries
 - 1,183 Italy
 - 724 United Kingdom
 - 382 France
 - 352 Spain
 - 302 Sweden
 - 161 United States




Agile scores are superior to histologic fibrosis stage and other fibrosis scores in prognostication

16 603 patients with MASLD from 16 centers in the US, Europe and Asia (prospective data from 14 centers)

316 liver-related events (LREs; 139 HCC and 209 hepatic decompensation) at a median FU of 52 months



Relative change in LSM and the risk of liver-related events in the VCTE-Prognosis study



*HR adjusted for baseline LSM

First VCTE	% change	% of patients	LRE per 1,000 py
Low LSM <10 kPa	>30% ↓	10%	1.4
	Stable	75%	0.7
	>30% ↑	15%	2.4
Intermediate LSM 10-15 kPa	>30% ↓	37%	0.7
	Stable	52%	7.4
	>30% ↑	11%	17.2
High LSM ≥15 kPa	>30% ↓	45%	16.1
	Stable	45%	33.3
	>30% ↑	10%	55.9

10.5x
 2.3x
 2.1x
 1.7x